190 related articles for article (PubMed ID: 20491777)
41. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
42. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
43. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
[TBL] [Abstract][Full Text] [Related]
44. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
45. The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
Putri A; Rinaldi I; Louisa M; Koesnoe S
Acta Med Indones; 2019 Oct; 51(4):348-352. PubMed ID: 32041920
[TBL] [Abstract][Full Text] [Related]
46. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
47. Getting to the stem of chronic myeloid leukaemia.
Savona M; Talpaz M
Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
[TBL] [Abstract][Full Text] [Related]
48. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
[TBL] [Abstract][Full Text] [Related]
49. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
Lenaerts T; Pacheco JM; Traulsen A; Dingli D
Haematologica; 2010 Jun; 95(6):900-7. PubMed ID: 20007137
[TBL] [Abstract][Full Text] [Related]
50. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
51. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
52. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
53. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
Huang R; Kang Q; Liu H; Li Y
Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
[TBL] [Abstract][Full Text] [Related]
54. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
55. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.
Lei H; Xu HZ; Shan HZ; Liu M; Lu Y; Fang ZX; Jin J; Jing B; Xiao XH; Gao SM; Gao FH; Xia L; Yang L; Liu LG; Wang WW; Liu CX; Tong Y; Wu YZ; Zheng JK; Chen GQ; Zhou L; Wu YL
Nat Commun; 2021 Jan; 12(1):51. PubMed ID: 33397955
[TBL] [Abstract][Full Text] [Related]
56. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
[TBL] [Abstract][Full Text] [Related]
58. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
[TBL] [Abstract][Full Text] [Related]
59. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
[TBL] [Abstract][Full Text] [Related]
60. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
O'Dwyer ME; La Rosée P; Nimmanapalli R; Bhalla KN; Druker BJ
Semin Hematol; 2002 Apr; 39(2 Suppl 1):18-21. PubMed ID: 12012318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
